Patient & caregiver support
Yolanda's Story
In my case, I went into complete remission with my KYPROLIS® combination.
YOLANDA: My loved ones, I told them in spurts.
YOLANDA: Despite me explaining what it was, they still didn’t get it. All they heard was the word cancer.
SUPER: Yolanda’s Story
YOLANDA: I found out I had multiple myeloma, then we started treatment.
YOLANDA: After a few years, I became stagnant. My numbers weren’t changing, so we decided that we needed to start KYPROLIS®.
SUPER: Yolanda’s story continues
VOICEOVER:
APPROVED USE:
- KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone, or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
IMPORTANT SAFETY INFORMATION
KYPROLIS® (carfilzomib) can cause serious side effects:
- Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
Please see additional Important Safety Information at the end of this video.
YOLANDA: Seeing that my labs actually were changing by using KYPROLIS® put me in a better way, that we were going in the right direction.
YOLANDA: In my case, I went into complete remission with KYPROLIS®.
YOLANDA: As I’ve gone through this, it helps to be fit and healthy.
YOLANDA: I was thinking about a career change, so while I would be hooked up to infusion, I would study for my fitness certification.
YOLANDA: So that’s my time, kind of just studying hard. And you know, thinking of the future.
YOLANDA: Now that I’m in remission, I’m looking forward to starting my own fitness business. It would be geared to those people who have chronic conditions.
YOLANDA: This seemed like a need for a person who specifically can work with someone like me.
YOLANDA: Multiple myeloma, it changes your world.
YOLANDA: I want people to know you can get through this. It hasn’t been easy, you know, this has been a journey, it still is a journey.
YOLANDA: I just would like to give people hope.
SUPER & VOICEOVER:
IMPORTANT SAFETY INFORMATION
KYPROLIS® (carfilzomib) can cause serious side effects:
- Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
- Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
- Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
- Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
- Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
- Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
- High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
- Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
- If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
- If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone, with lenalidomide plus dexamethasone, or with daratumumab and dexamethasone.
- Infusion-related reactions: Signs and symptoms of infusion-related reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, swelling of the larynx (voice box), vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
- Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
- Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
- Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
- Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
- Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
- Cases of a brain infection called Progressive Multifocal Leukoencephalopathy (PML), including fatal cases, have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms.
- KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
- Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should use effective contraception during treatment with KYPROLIS and for 6 months following the final dose. Men should use effective contraception during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
- Shortness of breath
- Prolonged, unusual or excessive bleeding
- Yellowing of the skin and/or eyes (jaundice)
- Headaches, confusion, seizures, or loss of sight
- Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
- Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
- The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, diarrhea, high blood pressure (hypertension), tiredness (fatigue), upper airway (respiratory tract) infection, low platelets, fever, cough, difficulty breathing and sleeplessness (insomnia).
These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088
APPROVED USE
- KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
SUPER:
KYPROLIS® Logo
©2022 Amgen Inc. All rights reserved.
USA-171-81851 September 2022
Karl's Story
My M-protein levels stayed low, and being stable is exactly where I want to be.
KARL: Well, from an emotional perspective, cancer in general is tough for a lot of people, and it’s tougher for some than others.
SUPER: Karl’s Story
KARL: This is not a simple disease to treat; it’s not a simple disease to deal with.
KATHLEEN: And I told him we’re in this together, and it was very important to take care of each other.
KARL: Well, I’m by nature an optimist. You know, so, for me, I’m always optimistic about how things are going to go.
KARL: I went to see my doctor because I had some severe pain in my right shoulder.
KARL: It was to the point where I could not lift my arm any higher than this, and so did some further tests on that and found out that I had multiple myeloma.
KARL: I started therapy, and then it just failed and all of a sudden my numbers went nuts.
KARL: And this other doc talked about, okay, what are we going to put this guy on now to get him under control?
KARL: And he said, I think right now the drug that’ll be best for you is KYPROLIS®.
SUPER: Karl’s story continues
VOICEOVER:
APPROVED USE:
- KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone, or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
IMPORTANT SAFETY INFORMATION
KYPROLIS® (carfilzomib) can cause serious side effects:
- Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
Please see additional Important Safety Information at the end of this video.
KARL: For me, it was a very easy decision to be on KYPROLIS® and to stay on KYPROLIS®.
KARL: I’m always the guy, you know, that I have to know where I am. It’s always important for me to know my status.
KARL: My primary tool as a blood marker is what’s called the M-protein. High or low, I know where I am.
KARL: While I was on KYPROLIS®, my M-protein level stayed at a low level, and being stable with myeloma is exactly where I want to be.
KARL: And Kathleen has always been there for those meetings with the doctor. So there was always really the three of us having the conversation as a team.
KATHLEEN: There were many challenging moments.
KATHLEEN: [LAUGHS] But you have to maintain your sense of each other, be there for each other…
KARL: And if you can manage that kind of relationship, still with the cancer as well, then you’re doing really, really well. And I think we think we’re doing really, really well. [LAUGHS]
SUPER & VOICEOVER:
IMPORTANT SAFETY INFORMATION
KYPROLIS® (carfilzomib) can cause serious side effects:
- Heart problems: KYPROLIS can cause heart problems or worsen pre-existing heart conditions. Death due to cardiac arrest has occurred within one day of KYPROLIS administration. Before starting KYPROLIS, you should have a full medical work-up (including blood pressure and fluid management). You should be closely monitored during treatment.
- Kidney problems: There have been reports of sudden kidney failure in patients receiving KYPROLIS. Your kidney function should be closely monitored during treatment.
- Tumor lysis syndrome (TLS): Cases of TLS have been reported in patients receiving KYPROLIS, including fatalities. You should be closely monitored during treatment for any signs of TLS.
- Lung damage: Cases of lung damage have been reported in patients receiving KYPROLIS, including fatal cases.
- Pulmonary hypertension (high blood pressure in the lungs): There have been reports of pulmonary hypertension in patients receiving KYPROLIS.
- Lung complications: Shortness of breath was reported in patients receiving KYPROLIS. Your lung function should be closely monitored during treatment.
- High blood pressure: Cases of high blood pressure, including fatal cases, have been reported in patients receiving KYPROLIS. Your blood pressure should be closely monitored during treatment.
- Blood clots: There have been reports of blood clots in patients receiving KYPROLIS. If you are at high risk for blood clots, your doctor can recommend ways to lower the risk.
- If you are using KYPROLIS in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone, your doctor should assess and may prescribe another medicine to help lower your risk for blood clots.
- If you are using birth control pills or other medical forms of birth control associated with a risk of blood clots, talk to your doctor and consider a different method of birth control during treatment with KYPROLIS in combination with dexamethasone, with lenalidomide plus dexamethasone, or with daratumumab and dexamethasone.
- Infusion-related reactions: Signs and symptoms of infusion-related reactions included fever, chills, joint pain, muscle pain, facial flushing and/or swelling, swelling of the larynx (voice box), vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, and chest pain. These symptoms can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. If you experience any of these symptoms, contact your doctor immediately.
- Severe bleeding problems: Fatal or serious cases of bleeding problems have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms of blood loss.
- Very low platelet count: Low platelet levels can cause unusual bruising and bleeding. You should have regular blood tests to check your platelet count during treatment.
- Liver problems: Cases of liver failure, including fatal cases, have been reported in patients receiving KYPROLIS. Your liver function should be closely monitored during treatment.
- Blood problems: Cases of a blood disease called thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal cases, have been reported in patients who received KYPROLIS. Your doctor should monitor your signs and symptoms.
- Brain problems: A nerve disease called Posterior Reversible Encephalopathy Syndrome (PRES), formerly called Reversible Posterior Leukoencephalopathy Syndrome (RPLS), has been reported in patients receiving KYPROLIS. It can cause seizure, headache, lack of energy, confusion, blindness, altered consciousness, and other visual and nerve disturbances, along with high blood pressure. Your doctor should monitor your signs and symptoms.
- Cases of a brain infection called Progressive Multifocal Leukoencephalopathy (PML), including fatal cases, have been reported in patients receiving KYPROLIS. Your doctor should monitor your signs and symptoms.
- KYPROLIS should not be combined with melphalan and prednisone: Newly diagnosed transplant ineligible multiple myeloma patients have shown an increased risk of serious and fatal side effects when using KYPROLIS in combination with melphalan and prednisone.
- Possible fetal harm: KYPROLIS can cause harm to a fetus (unborn baby) when given to a pregnant woman. Women should use effective contraception during treatment with KYPROLIS and for 6 months following the final dose. Men should use effective contraception during treatment with KYPROLIS and for 3 months following the final dose. KYPROLIS can cause harm to a fetus if used during pregnancy or if you or your partner become pregnant during treatment with KYPROLIS.
You should contact your doctor immediately if you experience any of the following:
- Shortness of breath
- Prolonged, unusual or excessive bleeding
- Yellowing of the skin and/or eyes (jaundice)
- Headaches, confusion, seizures, or loss of sight
- Pregnancy (women should not receive KYPROLIS if they are pregnant or breastfeeding)
- Any other side effect that bothers you or does not go away
What are the possible side effects of KYPROLIS?
- The most common side effects occurring in at least 20% of patients receiving KYPROLIS in the combination therapy trials are: low red blood cell count, diarrhea, high blood pressure (hypertension), tiredness (fatigue), upper airway (respiratory tract) infection, low platelets, fever, cough, difficulty breathing and sleeplessness (insomnia).
These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088
APPROVED USE
- KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, or isatuximab plus dexamethasone, which are other medicines used to treat multiple myeloma.
SUPER:
KYPROLIS® Logo
©2022 Amgen Inc. All rights reserved.
USA-171-81851 September 2022
Personalized support that you and your patients can count on across Amgen therapies
Connect with us live:
Monday through Friday — 8:30 AM to 8:00 PM ET
Financial Support
We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or the type of insurance they have.
What if my patient doesn’t have private or commercial insurance? Amgen® SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help.*
Learn more about how Amgen SupportPlus can help your patients access their prescribed medication. Visit AmgenSupportPlus.com to learn more.
*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen® has no control over these programs and provides information as a courtesy only.
Amgen® SupportPlus Co-Pay Program
The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs.
- Pay as little as $0* out-of-pocket for each dose
- Can be applied to deductible, co-insurance, and co-payment*
- No income eligibility requirement
Learn more about the ways Amgen SupportPlus can help you access your prescribed medication.
*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/Copay for full Terms and Conditions.
*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/Copay for full Terms and Conditions.
KYPROLIS® patient brochure
Get helpful information about how KYPROLIS® may help you live longer
Weekly treatment tracker for KYPROLIS® + Darzalex® (daratumumab) + dexamethasone
Help keep track of treatment and appointments
Weekly treatment tracker for KYPROLIS® + d (dexamethasone)
Help keep track of treatment and appointments
Weekly treatment tracker for KYPROLIS® + Rd (Revlimid® + dexamethasone)
Help keep track of treatment and appointments
Lab results tracker
Keep track of M-protein and other lab numbers